Psychedelic compounds, including psilocybin and MDMA (3,4-methylenedioxymethamphetamine) have emerged as promising novel treatments for depression and other psychiatric disorders. Research indicates that these agents may promote neuroplasticity, creating a unique opportunity to change patterns in brain activity, and in turn, improve symptoms, behavior and functioning. The Center for the Neuroscience of Psychedelics, a collaborative endeavor including researchers from the Department of Psychiatry, the Chemical Neurobiology Laboratory, and the Athinoula A. Martinos Center for Biomedical Imaging seeks to understand how psychedelics enhance the brain’s capacity for change, to optimize current treatments and create new treatments for mental illness, and to make the term “treatment resistant” obsolete.
The atai Fellowship Fund in Psychedelic Neuroscience within the Center for the Neuroscience of Psychedelics at MGH will provide graduate students and other trainees with time and resources to pursue cutting-edge research to uncover the fundamental mechanisms of action and key properties of therapeutic psychedelics and other neuroplasticity modulators. Fellows will be partnered with a researcher in the preferred field of study.
Learn more about the atai Fellowship and about research at the Center for the Neuroscience of Psychedelics (interview with Jerry Rosenbaum, MD).
Read More
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics (Globe Newswire)
New center seeks to understand any ‘magic’ in mushrooms (The Harvard Gazette)
